Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nutritional Science

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Nutritional Science. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-002282-19 Sponsor Protocol Number: MENAC-2017-03 Start Date*: 2016-05-17
    Sponsor Name:Norwegian University of Science and technology
    Full Title: A randomised, open-label trial of a Multimodal Intervention (Exercise, Nutrition and Anti-inflammatory Medication) plus standard care versus standard care alone to prevent / attenuate cachexia in a...
    Medical condition: cachexia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004691-22 Sponsor Protocol Number: RCT-004 Start Date*: 2017-11-21
    Sponsor Name:Rechon Life Science AB
    Full Title: A Randomised, Open, Parallel-group Phase III Biosimilarity Study to Assess the Long-term Safety, Focusing on Immunogenicity, of Rechon Insulin Human Soluble in Type 1 Diabetic Patients.
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000315-91 Sponsor Protocol Number: RG_18-236 Start Date*: 2019-09-09
    Sponsor Name:University of Birmingham
    Full Title: The pAToMiUM Trial: pilot trial of Antioxidant Therapy of Men in Unexplained Miscarriage
    Medical condition: Unexplained miscarriage and how this may relate to the quality of the sperm DNA at conception, with particular emphasis on chromatin structure and DNA fragmentation and whether this may be improved...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10065877 Dietary and nutritional therapies HLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-005125-12 Sponsor Protocol Number: LIRALUNG Start Date*: 2016-05-12
    Sponsor Name:Dr. Albert Lecube, Ph.D., M.D.
    Full Title: MULTICENTRE RANDOMIZED DOUBLE BLIND, CROSSOVER, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFECT OF LIRAGLUTIDE ON LUNG FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (LIRALUNG STUDY)
    Medical condition: Type 2 Diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003426-24 Sponsor Protocol Number: CTU079G Start Date*: 2013-02-13
    Sponsor Name:Riemser Pharma GmbH
    Full Title: A multicentre double blind placebo controlled clinical trial to assess efficacy and safety of Alvalin® (cathine hydrochloride) vs. placebo in 265 obese patients/group with a body mass index (BMI) b...
    Medical condition: diet-related obesity diagnosed by BMI of 30 to 45 kg/m²
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002766-50 Sponsor Protocol Number: ProTrans-T1D Start Date*: 2017-10-12
    Sponsor Name:NextCell Pharma
    Full Title: A DOUBLE-BLINDED, RANDOMIZED, PARALLEL, PLACEBO-CONTROLLED TRIAL OF WHARTON’S JELLY DERIVED ALLOGENEIC MESENCHYMAL STROMAL CELLS TO PRESERVE ENDOGENOUS INSULIN PRODUCTION IN ADULT PATIENTS DIAGNOSE...
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012594 Diabetes LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017080-41 Sponsor Protocol Number: GWMD09112 Start Date*: 2010-04-19
    Sponsor Name:GW Pharma Ltd.
    Full Title: A randomised, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease.
    Medical condition: Subjects with fatty liver disease (≥ 5% liver fat levels).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10019805 - Hepatobiliary disorders 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020458-33 Sponsor Protocol Number: GWMD1092 Start Date*: 2010-08-05
    Sponsor Name:GW Pharma Ltd.
    Full Title: A randomised, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GW42003: GW42004 plus GW42003 and GW42004 alone in the treatment of dyslipidaemia in ...
    Medical condition: Dyslipidaemia in subjects with type 2 diabetes who have failed to achieve satisfactory lipid control with existing therapies.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002181-32 Sponsor Protocol Number: RG012-03 Start Date*: 2016-12-07
    Sponsor Name:Regulus Therapeutics Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of Weekly RG 012 Injections in Pat...
    Medical condition: Alport syndrome is an inherited form of kidney disease caused by mutations in genes coding for the capillary basement membrane collagen IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004158-11 Sponsor Protocol Number: ProTrans2-T1D Start Date*: 2019-03-25
    Sponsor Name:NextCell Pharma
    Full Title: AN OPEN LABEL, PARALLEL SINGLE CENTRE TRIAL OF WHARTON’S JELLY DERIVED ALLOGENEIC MESENCHYMAL STROMAL CELLS REPEATED TREATMENT TO PRESERVE ENDOGENOUS INSULIN PRODUCTION IN ADULT PATIENTS DIAGNOSED ...
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012594 Diabetes LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000897-36 Sponsor Protocol Number: AB14005 Start Date*: 2016-04-26
    Sponsor Name:AB science
    Full Title: A prospective, multicentre, double-blind, randomized, placebo-controlled, phase 3 study to evaluate efficacy and safety of masitinib with irinotecan in patients with advanced-stage esophagogastric ...
    Medical condition: Πatients with advanced-stage esophagogastric adenocarcinoma who have relapsed after first-line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10017776 Gastric carcinoma stage III LLT
    18.1 100000004864 10017777 Gastric carcinoma stage IV NOS LLT
    18.1 100000004864 10017778 Gastric carcinoma stage IV without metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-000491-14 Sponsor Protocol Number: AB12008 Start Date*: 2014-10-10
    Sponsor Name:AB Science
    Full Title: A prospective, multicentre, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alo...
    Medical condition: Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third line
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033158 Ovarian epithelial cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) FR (Ongoing) GB (GB - no longer in EU/EEA) SK (Prohibited by CA) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022897-14 Sponsor Protocol Number: PreMENAC-2011-01 Start Date*: 2011-05-02
    Sponsor Name:Dep. of Cancer Research and Molecular medicine, Norwegian University of Science and Technology
    Full Title: PreMENAC: Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia: A feasibility study (phase II)
    Medical condition: Diagnosis of non operable non-small cell lung cancer NSCLC (stage III-IV) or pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000180-28 Sponsor Protocol Number: GWMD09126 Start Date*: 2011-07-12
    Sponsor Name:GW Pharma Ltd
    Full Title: A randomised, double-blind, placebo-controlled parallel group, pilot study of 40:1 ratio of formulated GWP42003 : GWP42004 in the treatment of iatrogenic weight gain and dyslipidaemia associated wi...
    Medical condition: Iatrogenic weight gain and dyslipidaemia associated with treatment using antipsychotic medication
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10058110 Dyslipidemia LLT
    14.1 10022891 - Investigations 10047896 Weight gain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003577-26 Sponsor Protocol Number: U1111-1131-5236 Start Date*: 2012-10-24
    Sponsor Name:Aarhus University Hospital
    Full Title: Liraglutide Kidney: A randomised, double-blinded, cross-over study investigating the short-term impact of liraglutide on kidney function in diabetic patients
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2023-000785-33 Sponsor Protocol Number: HST20-CL01 Start Date*: 2023-08-18
    Sponsor Name:HemoShear Therapeutics
    Full Title: A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects with Propionic or Methylmalonic Acidemia Followed by a 6-Month, Randomized, Double-blind, Placebo-controlled, 2-Period Crossover S...
    Medical condition: Methylmalonic Acidemia (MMA) Propionic Acidemia (PA)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019821-32 Sponsor Protocol Number: 20090508 Start Date*: 2010-11-04
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fa...
    Medical condition: Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancers
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Completed) PT (Completed) CZ (Prematurely Ended) SI (Completed) GR (Completed) SE (Completed) LV (Completed) EE (Completed) IT (Completed) BG (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001454-33 Sponsor Protocol Number: DEXBASU Start Date*: 2017-08-07
    Sponsor Name:Dr. Albert Lecube Torello
    Full Title: A randomized, non-blinded, 24-week pilot study to evaluate the effect of dapagliflozin (10 mg once daily) plus exenatide (2.0 mg once weekly) on type 2 diabetic patients awaiting for bariatric surg...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001081-38 Sponsor Protocol Number: ARCT-810-03 Start Date*: 2021-12-23
    Sponsor Name:Arcturus Therapeutics, Inc.
    Full Title: Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult ...
    Medical condition: Ornithine transcarbamylase deficiency
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004850 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) ES (Ongoing) SE (Restarted) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001382-32 Sponsor Protocol Number: 20100761 Start Date*: 2012-06-19
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Explore Dose Effect and Frequency of Administration of AMG 151 in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:31:28 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA